GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exicure Inc (STU:2H0A) » Definitions » Investments And Advances

Exicure (STU:2H0A) Investments And Advances : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Exicure Investments And Advances?

Exicure's Investments And Advances for the quarter that ended in Dec. 2023 was €0.00 Mil.

Exicure's quarterly Investments And Advances declined from Jun. 2023 (€1.85 Mil) to Sep. 2023 (€0.00 Mil) but then stayed the same from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).


Exicure Investments And Advances Historical Data

The historical data trend for Exicure's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exicure Investments And Advances Chart

Exicure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial - - - - -

Exicure Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 1.85 - -

Exicure Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Exicure (STU:2H0A) Business Description

Traded in Other Exchanges
Address
2430 N. Halsted Street, Suite 410, Chicago, IL, USA, 60614
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.

Exicure (STU:2H0A) Headlines

No Headlines